Fibrobiologics Inc (FBLG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,646 | -11,161 | -16,485 | -5,121 | -1,582 |
| Depreciation Amortization | 832 | 573 | 518 | 483 | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | 141 | N/A | N/A |
| Other Working Capital | -3,312 | 2,422 | 493 | 307 | 172 |
| Other Operating Activity | 4,732 | -3,735 | 8,932 | 265 | 0 |
| Operating Cash Flow | $-16,394 | $-11,901 | $-6,401 | $-4,066 | $-1,410 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -262 | -184 | -495 | N/A | N/A |
| Investing Cash Flow | $-262 | $-184 | $-495 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,375 | 9,974 | N/A | 4,300 | 2,275 |
| Common Stock Issued | 6,590 | 7,507 | N/A | N/A | N/A |
| Other Financing Activity | -3,400 | -574 | 13,793 | 1,625 | -458 |
| Financing Cash Flow | $7,565 | $16,907 | $13,793 | $5,925 | $1,817 |
| Beginning Cash Position | 13,985 | 9,163 | 2,266 | 407 | N/A |
| End Cash Position | 4,894 | 13,985 | 9,163 | 2,266 | 407 |
| Net Cash Flow | $-9,091 | $4,822 | $6,897 | $1,859 | $407 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,394 | -11,901 | -6,401 | -4,066 | -1,410 |
| Capital Expenditure | -262 | -184 | -495 | N/A | N/A |
| Free Cash Flow | -16,656 | -12,085 | -6,896 | -4,066 | -1,410 |